Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial.

Autor: Bue-Valleskey JM; 1Eli Lilly and Company, Indianapolis, IN., Kazda CM; 2Lilly France, Neuilly sur Seine, France., Ma C; 1Eli Lilly and Company, Indianapolis, IN., Chien J; 1Eli Lilly and Company, Indianapolis, IN., Zhang Q; 1Eli Lilly and Company, Indianapolis, IN., Chigutsa E; 1Eli Lilly and Company, Indianapolis, IN., Landschulz W; 1Eli Lilly and Company, Indianapolis, IN., Haupt A; 1Eli Lilly and Company, Indianapolis, IN., Frias JP; 3Velocity Clinical Research, Los Angeles, CA.

Publikováno v: Diabetes care [Diabetes Care] 2023 May 01; Vol. 46 (5), pp. 1060-1067.

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.

Autor: Guzman CB; Eli Lilly and Company Indianapolis IN.; Present address: Enanta Pharmaceuticals Inc Watertown MA., Duvvuru S; Eli Lilly and Company Indianapolis IN.; Present address: Amazon Seattle WA., Akkari A; Cabernet Pharmaceuticals Durham NC., Bhatnagar P; Eli Lilly and Company Indianapolis IN., Battioui C; Eli Lilly and Company Indianapolis IN., Foster W; Eli Lilly and Company Indianapolis IN., Zhang XM; Eli Lilly and Company Toronto Canada., Shankar SS; Eli Lilly and Company Indianapolis IN.; Present address: NGM Biopharmaceuticals San Francisco CA., Deeg MA; Eli Lilly and Company Indianapolis IN.; Present address: Regulus Pharmaceuticals San Diego CA., Chalasani N; Indiana University Department of Medicine Indianapolis IN., Hardy TA; Eli Lilly and Company Indianapolis IN., Kazda CM; Eli Lilly and Company Neuilly sur Seine France., Pillai SG; Eli Lilly and Company Indianapolis IN.

Publikováno v: Hepatology communications [Hepatol Commun] 2018 Mar 23; Vol. 2 (5), pp. 561-570. Date of Electronic Publication: 2018 Mar 23 (Print Publication: 2018).

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.

Autor: Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA

Publikováno v: Diabetes care [Diabetes Care] 2017 Jun; Vol. 40 (6), pp. 808. Date of Electronic Publication: 2017 Apr 18.

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.

Autor: Kazda CM; Eli Lilly and Company, Suresnes, France kazda_christof@lilly.com., Ding Y; Eli Lilly and Company, Indianapolis, IN., Kelly RP; Lilly-NUS Centre for Clinical Pharmacology, Singapore., Garhyan P; Eli Lilly and Company, Indianapolis, IN., Shi C; inVentiv Health Clinical, Clarksville, MD., Lim CN; Eli Lilly and Company, Indianapolis, IN., Fu H; Eli Lilly and Company, Indianapolis, IN., Watson DE; Eli Lilly and Company, Indianapolis, IN., Lewin AJ; National Research Institute, Los Angeles, CA., Landschulz WH; Eli Lilly and Company, Indianapolis, IN., Deeg MA; Eli Lilly and Company, Indianapolis, IN., Moller DE; Eli Lilly and Company, Indianapolis, IN., Hardy TA; Eli Lilly and Company, Indianapolis, IN.

Publikováno v: Diabetes care [Diabetes Care] 2016 Jul; Vol. 39 (7), pp. 1241-9. Date of Electronic Publication: 2015 Dec 17.